Tacrolimus in liver transplantation

Bibliography

• KINO T, HATANAKA H, HASHIMOTO H et al: FK-506, a novel immunosuppressant isolated from a Strepto-myces, I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. (1987) 40:1249–1255.
   Google Scholar
• STARZL T, TODO S, FUNG J et al: FK506 for liver, kidney, and pancreas transplantation. Lancet (1989) 2:1000–1004.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet (1994) 344:423–428.
   PubMed Web of Science ®Google Scholar
• ••Results of the multicentre randomised trial comparingtacrolimus and cyclosporin: the European experience.
   Google Scholar
• ANONYMOUS: A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group [see comments]. New Engl. J. Med. (1994) 331:1110–1115.
   Google Scholar
• ••Results of the multicentre randomised trial comparingtacrolimus and cyclosporin: the US experience.
   Google Scholar
• FUNGI ABU-ELMAGD K, JAIN A et al.: A randomized trial of primary liver transplantation under immunosup-pression with FK 506 vs cyclosporine. Transplant. Proc. (1991) 23:2977–2983.
   PubMed Web of Science ®Google Scholar
• NISHIYAMA M, IZUMI S, OKUHARA M: Discovery and development of FK506 (tacrolimus), a potent immunosuppressant of microbial origin. In: The Search for AntiInflammatory Drugs, VJMAJ Adams (Ed.), (1995):65–104.
   Google Scholar
• THOMSON AW, WHITING PH, SIMPSON JG:Cyclosporine A. DJG White, (Ed.), Elsevier Biomedical, New York, USA (1982):177.
   Google Scholar
• OCHAI T, NAKAJIMA K, NAGATA M: Effect of a newimmunosuppressive agent, FK506 on heterotopic cardiac allotransplantation in the rat. Transplant. Proc. (1987) 19:1284–1286.
   PubMed Web of Science ®Google Scholar
• TANAKA H, KURODA A, MARUSAWA H et al.: Structure ofFK506: A novel immunosuppressant isolated from Streptomyces. J. Am. Chem. Soc. (1987) 109:5031–5033.
   Web of Science ®Google Scholar
• TOCCONI MJ, MATKOVICH DA, COLLIER KA et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol. (1989) 143:718–726.
   PubMed Web of Science ®Google Scholar
• KINO T, INAMURA N, SAKAI F et al.: Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transpl Proc. (1987) 19:36–39.
   PubMed Web of Science ®Google Scholar
• HUTCHINSON I: Transplantation and rejection. In: Immonology 3rd Ed., I Roitt, J Brostoff, & D Male (Eds.), Mosby (1993):23.21–23.14.
   Google Scholar
• BRAM RJ, HUNG DT, MARTIN PK, SCHREIBER SL, CRABTREE GR: Identification of the immunophiles capable of mediating inhibition of signal transduction by cyclosporin A and FK506: Roles of calcineurin binding and cellular location. Mol. Cell Biol. (1993) 13:4760–4769.
   PubMed Web of Science ®Google Scholar
• LIU J, FARMER JD, LANE WS et al.: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell (1991) 66:807–815.
   PubMed Web of Science ®Google Scholar
• •Description of the common target of the cyclosporin and tacrolimus complexes.
   Google Scholar
• FLANAGAN WM, CORTHESY B, BRAM RJ, CRABTREE GR: Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature (1991) 352:803–807.
   PubMed Web of Science ®Google Scholar
• DEFRANCO AL: Immunosuppressants at work. Nature (1991) 352:754–755.
   PubMed Web of Science ®Google Scholar
• ADAMS DH, Liu Q: FK506 inhibits human lymphocyte migration and the production of lymphocyte chemotactic factors in liver allograft recipients. Hepatology (1996) 23:1476–1483.
   PubMed Web of Science ®Google Scholar
• ADAMS DH, WANG LF, NEUBERGER JM, ELIAS E: Inhibi-tion of leucocyte chemotaxis by immunosuppressive agents: specific inhibition of lymphocyte chemotaxis by cyclosporine. Transplantation (1990) 50:845–850.
   PubMed Web of Science ®Google Scholar
• JAIN A, VENKATARAMANAN R, CADOFF E et al.: Effect of hepatic dysfunction and T tube clamping on FK506 pharmacokinetics and trough concentrations. Transpl. Proc. (1990) 22:57–59.
   PubMed Web of Science ®Google Scholar
• VENKATARAMANAN R, JAIN A, WARTY VS eta].: Pharma-cokinetics of FK 506 in transplant patients. Transpl. Proc. (1991) 23:2736–2740.
   Google Scholar
• SEWING KF: Pharmacokinetics, dosing principles, and blood level monitoring of FK506. Transpl. Proc. (1994) 26:3267–3269.
   PubMed Web of Science ®Google Scholar
• SATTLER M, GUENGERICH FP, YUN CH, CHRISTIANS U,SEWING KF: Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metabol Disposit. (1992) 20:753–761.
   PubMed Web of Science ®Google Scholar
• LAMPEN A, CHRISTIANS U, GUENGERICH FP et al.: Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interac-tions, and interindividual variability. Drug Metabol Disposit. (1995) 23:1315–1324.
   PubMed Web of Science ®Google Scholar
• GONSCHIOR AK, CHRISTIANS U, WINKLER M et al.: Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin. Chem. (1996) 42:1426–1432.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Pharmacokinetics of prograf. In: Prograf (Tacrolimus) product monograph. Gardiner-Caldwell Communication Ltd, Fujisawa (1997):15–19.
   Google Scholar
• WINKLER M, WONIGEIT K, UNDRE N et al: Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. Transpl. Proc. (1995) 27:822–825.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ M, HOLST B, FACKLAM D, BUELL D: FK 506 inliver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. Transpl. Proc. (1995) 27:1107.
   Google Scholar
• BACKMAN L, LEVY MF, KLINTMALM G: Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. Transpl. Proc. (1995) 27:1124.
   Google Scholar
• KERSHNER RP, FITZSIMMONS WE: Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation (1996) 62:920–926.
   PubMed Web of Science ®Google Scholar
• FUNG JJ, ELIASZIW M, TODO S et al.: The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J. Am. Coll. Surg. (1996) 183:117–125.
   PubMed Web of Science ®Google Scholar
• •Trial data comparing tacrolimus and cyclosporin, but with considerable problems in design.
   Google Scholar
• TODO S, FUNG JJ, STARZL TE eta].: Single-center experi-ence with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann. Surg. (1994) 220:297–308.
   Google Scholar
• STARZL TE, DONNER A, ELIASZIW M et al: Randomisedtrialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 346:1346–1350.
   PubMed Web of Science ®Google Scholar
• •Discussion of trial data concerning tacrolimus.
   Google Scholar
• RANDAL EM, BYRON WBJ: Tacrolimus for prevention of liver allograft rejection: clinical trial and tribulations. Lancet (1995) 346:1310–1311.
   PubMed Web of Science ®Google Scholar
• ••Useful discussion addressing the problems of multicentretrials.
   Google Scholar
• WILLIAMS R, NEUHAUS P, BISMUTH H et al.: Two-year data from the European multicentre tacrolimus (FK506) liver study. Transpl. Int. (1996) 9:S144–150.
   PubMedGoogle Scholar
• PICHLMAYR R, WINKLER M, NEYHAUS P et al.: Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study. Transplant. Proc. (1997) 29:2499–2502.
   PubMed Web of Science ®Google Scholar
• WIESNER RH: Tacrolimus vs cyclosporine in liver transplantation: five-year follow up of the U.S. Phase III, comparative randomized study. In: 16th Annual Meeting Scientific Sessions & Business Meeting, American Society of Transplant Physicians Chicago, USA (1997).
   Google Scholar
• BUSUTTIL RW, HOLT CD: Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. Transplant. Proc. (1997) 29:534–538.
   PubMed Web of Science ®Google Scholar
• JAIN AB, FUNG JJ, TODO S et al.: One thousand consecu-tive primary orthotopic liver transplants under FK 506: survival and adverse events. Transplant. Proc. (1995) 27:1099–1104.
   PubMed Web of Science ®Google Scholar
• MCDIARMID SV, BUSUTTIL RW, ASCHER NL et al.: FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplanta-tion. Results from the U.S. Multicenter Trial. Transplant. (1995) 59:530–536.
   Google Scholar
• BISMUTH H: Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy signifi-cantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. Transplant. Proc. (1995) 27:45–49.
   Google Scholar
• ALESSIANI M, KUSNE S, Martin M et al.: Infections in adult liver transplant patients under FK506 immunosup-pression. Transpl. Proc. (1991) 23:1501–1503.
   PubMed Web of Science ®Google Scholar
• KUSNE S, FUNG J, ALESSIANI M eta].: Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. Transplant. Proc. (1992) 24:429–430.
   Google Scholar
• NEUHAUS P, LANGREHR JM, WILLIAMS R et al.:Tacrolimus-based immunosuppression after liver transplantation: a randomised study comparing dual versus triple low-dose oral regimens. Transpl. Int. (1997) 10:253–261.
   PubMed Web of Science ®Google Scholar
• ECKHOFF D, McGUIRE BM, FRENETTE LC et al.:Tacrolimus (FK506) and mycophenolate mefetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation (1998) 65:180–187.
   PubMed Web of Science ®Google Scholar
• WIESNER RH, LUDWIG J, VAN HOEK B, KROM R: Currentconcepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology (1991) 14:721–729.
   PubMed Web of Science ®Google Scholar
• FREESE DK, SNOVER DC, SHARP HL et al.: Chronicrejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology (1991) 13:882–891.
   PubMed Web of Science ®Google Scholar
• VAN HOEK B, WIESNER RH, F. KRA, LUDWIG J, B MS:Severe ductopenic rejection following liver transplan-tation: incidence, time of onset, risk factors, treatment, and outcome. Seminars in liver disease (1992) 12:41–50.
   Google Scholar
• HUBSCHER S, NEUBERGER J: Chronic rejection of theliver allograft. In: Immunology of Liver Transplantation. J Neuberger & D Adams (Eds.) (1993):216–229.
   Google Scholar
• MILLIS JM, WOODLE ES, PIPER JB et al: Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation (1996) 61:1365–1369.
   PubMed Web of Science ®Google Scholar
• BUSUTTIL RW: FK506 (tacrolimus, progra0 as rescue therapy in liver transplant patients with drug-resistant immune rejection. Hepatology (1995) 22: Abstract 398A.
   Google Scholar
• SHER LS, COSENZA CA, MICHEL J et al: Efficacy oftacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. Transplantation (1997) 64:258–263.
   Google Scholar
• JAIN A, FUNG JJ, TODO S et al: More than six yearsactual follow-up: conversion from cyclosporine to tacrolimus for chronic liver allograft rejection. Hepatology (1996) 24: Abstract 218:181A.
   Google Scholar
• KLINTMALM1 GB, GOLDSTEIN R, GONWA T et al: Use ofPrograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transpl. Proc. (1993) 25:679–688.
   Google Scholar
• PLATZ KP, MUELLER AR, ZYTOWSKI H et al.: FK506 forprimary and rescue therapy following liver transplan-tation. In: The international congress on imrnunosuppres-sion. (1997) Florida, USA.
   Google Scholar
• PLATZ KP, MUELLER R, NEUHAUS R et al.: FK506 andmycophenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplanta-tion. Transpl. Proc. (1997) 29:2872–2874.
   PubMed Web of Science ®Google Scholar
• PORAYKO MK, TEXTOR SC, KROM RA et al.: Nephrotox-icity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients. Transpl. Proc. (1993) 25:665–668.
   PubMed Web of Science ®Google Scholar
• MCDIARM SV, COLONNA J0d, SHAKED A, AMENT ME,BUSUTTIL RW: A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. Transplanta-tion (1993) 56:847–853.
   PubMed Web of Science ®Google Scholar
• KUSTER GM, DREXEL H, BLEISCH JA: Relation ofcyclosporin blood levels to adverse effects on lipopro-teins. Transplantation (1994) 57:1479–1483.
   PubMed Web of Science ®Google Scholar
• ABOULJOUD MS, LEVY MF, KLINTMALM GB: Hyperlipi-demia after liver transplantation: long-term results of the FK506/cyclosporine a US Multicenter trial. US Multicenter Study Group. Transpl. Proc. (1995) 27:1121–1123.
   PubMed Web of Science ®Google Scholar
• MORE, FACKLAM D, HASSE J et al.: Weight gain and lipidprofile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. Transpl. Proc. (1995) 27:1126.
   PubMed Web of Science ®Google Scholar
• VAN THIEL DH, LQBAL M, JAIN A et al.: Gastrointestinaland metabolic problems associated with immunosup-pression with either CyA or FK506 in liver transplanta-tion. Transpl. Proc. (1990) 22:37–40.
   PubMed Web of Science ®Google Scholar
• STRATTA RJ, SHAEFER MS, CUSHING KA et al.: A random-ized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch. Surg. (1992) 127:55–63.
   PubMed Web of Science ®Google Scholar
• SHAPIRO R, FUNG JJ, JAIN AB et al: The side effects of FK506 in humans. Transplant. Proc. (1990) 22:35–36.
   PubMed Web of Science ®Google Scholar
• JAIN A, VENKATARAMANAN R, LEVER J et al.: FK506 and pregnancy in liver transplant patients [corrected and republished article originally printed in Transplanta-tion 1993 Sep;56(3):751]. Transplantation (1993) 56:1588–1589.
   PubMedGoogle Scholar
• WINKLER ME, NIESERT S, RINGE B, PICHLMAYR R: Successful pregnancy in a patient after liver transplan-tation maintained on FK 506 [corrected and republished article originally printed in Trnasplanta-tion 1993 Sep;56(3):751-3]. Transplantation (1993) 56:1589–1590.
   PubMedGoogle Scholar
• JAIN A, VENKATARAMANAN R, FUNG JJ et al: Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 64:559–565.
   PubMed Web of Science ®Google Scholar
• DAVIES MH: Immunosuppressive drugs. In: Liver transplantation: practice and management, J Neuberger .3,z M Lucey (Eds.), BMJ (1994).
   Google Scholar
• LAKE JR, GORMAN KJ, ESQUIVEL CO et al.: The impact of immunosuppressive regimens on the cost of liver transplantation-results from the U.S. FK506 multicenter trial. Transplantation (1995) 60:1089–1095.
   Google Scholar
• MCKENNA M, ALEXANDER G, JONES M, HUTTON J: Economic analysis of tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Euro. Hosp. Pharm. (1996) 2:1–8.
   Google Scholar
• STASCHAK S, WAGNER S, BLOCK G et al.: A cost comparison of liver transplantation with FK506 or CyA as the primary immunosuppressive agent. Transplant. Proc. (1990) 22:47–49.
   PubMed Web of Science ®Google Scholar
• POLLARD SG, LODGE JP: Conversion from Sandim-mune to Neoral in stable liver graft recipients. Transpl. Proc. (1996) 28:2244–2246.
   PubMed Web of Science ®Google Scholar
• POLLARD SG, LODGE JP: Optimization of cyclosporine therapy in liver transplantation. Transplantation Proceedings (1998) 30:1816–1818.
   PubMed Web of Science ®Google Scholar
• BUSUTTIL RW, HOLT CD: Tacrolimus is superior to cyclosporine in liver transplantation. Transplant. Proc. (1998) 30:2174–2178.
   PubMed Web of Science ®Google Scholar
• •Transplant proceedings.
   Google Scholar